Seattle, WA | January 8, 2015
FOR IMMEDIATE RELEASE: SEATTLE, January 8, 2015: IDRI (Infectious Disease Research Institute) is expanding its Board of Directors, comprised of international leaders in industry and academia, with the recent addition of Bruce L.A. Carter, Ph.D., who has more than 25 years of progressive experience in the biotech and pharmaceutical industries. At IDRI’s most recent board meeting, Carter was elected as Board Chair and will serve on IDRI’s executive committee along with Franklyn Prendergast, professor at the Mayo Medical School, and David Perry, president and CEO of Symbiota.
“Dr. Carter’s wealth of knowledge, scientific expertise and executive management experience makes him a terrific addition to IDRI’s board,” said Steven G. Reed, Ph.D., IDRI Founder, President and Chief Scientific Officer. “With our focus on developing products to solve global health challenges caused by infectious diseases, IDRI will benefit from Bruce’s extensive experience in the pharmaceutical industry.”
Carter began his career in drug discovery at G.D. Searle and later joined ZymoGenetics, Inc., where he served as president from 1988 to 1994 when Novo Nordisk acquired the company. At Novo Nordisk, Carter was Corporate Executive Vice President and Chief Scientific Officer until 2000 when he led a buyout of ZymoGenetics, establishing it as an independent company from Novo Nordisk. He was named President and Chief Executive Officer and led ZymoGenetics’ successful development and commercialization of Recothrom ®, a recombinant thrombin for use during surgical procedures. Bristol-Myers Squibb acquired ZymoGenetics in 2008. Most recently, Dr. Carter was Executive Chairman of Immune Design Corp. from 2009 to 2011.
“I am pleased to join the board of IDRI, with its global health mission of developing not only diagnostics, but vaccines and drugs as well,” said Carter. “When I retired, I wanted to do something for others and thought the area of infectious diseases would be a good place to start. My mother lost three sisters within the space of one year to tuberculosis, so I have a personal reason for wanting to contribute in this area, as well.”
In addition to being a member of IDRI’s Board of Directors, Carter serves on a number of corporate boards, including Dr. Reddy’s Laboratories Ltd., in Hyderabad, India. IDRI also recently announced the addition of another new board member, Michel De Wilde, Ph.D., who serves as a consultant for the international vaccine community and is a former senior vice president at Sanofi Pasteur.
As a non-profit global health organization, IDRI (Infectious Disease Research Institute) takes a comprehensive approach to combat infectious diseases, combining the high-quality science of a research organization with the product development capabilities of a biotech company to create new diagnostics, drugs and vaccines. IDRI combines passion for improving human health with the understanding that it is not just what our scientists know about disease, but what we do to change its course that will have the greatest impact. Founded in 1993, IDRI has 125 employees headquartered in Seattle with nearly 100 partners/collaborators around the world. For more information, visit www.idri.org.
IDRI: Lee Schoentrup | 206.858.6064 | email@example.com